Bestatin selectively suppresses the growth of leukemic stem/progenitor cells with BCR/ABL mRNA transcript in patients with chronic myelogeneous leukemia

International Immunopharmacology

Volumn 3, Issue 6, 2003, Pages 901-907

  Fujisaki, Tomoaki ^a,c   Otsuka, Teruhisa ^a   Gondo, Hisashi ^a   Okamura, Takashi ^a   Niho, Yoshiyuki ^a   Ohhinata, Akira ^b   Abe, Fuminori ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

Bestatin; Chronic myeloid leukemia; In vitro purging; Long term culture

Indexed keywords

BESTATIN;

ARTICLE; CELL CULTURE; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLONE; CLONOGENESIS; DNA ISOLATION; DRUG MECHANISM; ERYTHROID PRECURSOR CELL; GROWTH INHIBITION; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

EID: 0038392597     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00083-3     Document Type: Article

References (23)

1. Rowley J.D. A new consistent chromosome abnormality in chronic myelogeneous leukaemia detected by quinacrine fluorescence and Giemsa staining. Nature. 243:1973;290-293.
2. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 36:1984;93-99.
3. Ben-Neriah Y., Daley G.Q., Mes-Masson A.-M., Witte O.N., Baltimore D. The chronic myelogeneous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science. 233:1986;212-214.
4. Barnett M.J., Eaves C.J., Phillips G.L., Gascoyne R.D., Hogge D.E., Horsman D.E.et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood. 84:1994;724-732.
5. Udomsakdi C., Eaves C.J., Swolin B., Reid D.S., Barnett M.J., Eaves A.C. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc. Natl. Acad. Sci. U. S. A. 89:1992;6192-6196.
6. Smith M.A., Mills K.I., Smiyh J.G. Long-term culture and molecular biological studies highlight differences in relative BCR-ABL expression levels in the peripheral blood and bone marrow of a patient with chronic granulocytic leukemia. Br. J. Haematol. 88:1994;406-408.
7. - haemopoiesis in long-term bone marrow culture for patients with chronic myeloid leukaemia on conventional hydoxyurea therapy, on pulse high-dose hydroxyurea and on interferon-alpha. Br. J. Haematol. 93:1996;869-877.
8. Brandwein J.M., Dube I.D., Laraya P., Keating A. Maintenance of Philadelphia chromosome positive progenitors in long-term marrow cultures from patients with advanced chronic myeloid leukemia. Leukemia. 6:1992;556-561.
9. Ota K., Kurita S., Yamada K., Masaoka T., Uzuka Y., Ogawa N. Immunotherapy with Bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol. Immunother. 23:1986;5-10.
10. Fujisaki T., Otsuka T., Takamatsu Y., Eto T., Harada M., Niho Y. Effects of Bestatin on hematopoiesis in long-term human bone marrow cultures. Biomed. Pharmacother. 49:1995;69-74.
11. Bierman P.J., Abe F., Buyukberber S., Ino K., Talmadge J.E. Partial review of immunotherapeutic pharmacology in stem cell transplantation. In Vivo. 14:2000;221-226.
12. Uzuka Y., Saito Y. Combination therapy of chronic myelogeneous leukemia with Busulfan and Bestatin. Jpn. J. Cancer Chemother. 18:1991;571-578.
13. Fujisaki T., Otsuka T., Harada M., Ohno Y., Niho Y. Granulocyte colony-stimulating factor mobilizes primitive hematopoietic stem cells in normal individuals. Bone Marrow Transplant. 16:1995;57-62.
14. Kawasaki E.S., Clark S.S., Coyne M.Y., Smith S.D., Champlin R., Witte O.N.et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5698-5702.
15. Allieri M.A., Fabrega S., Ozsahin H., Douay L., Barbu V., Gorin N.C. Detection of BCR/ABL translocation by polymerase chain reaction in leukemic progenitor cells (ALL-CFU) from patients with acute lymphoblastic leukemia (ALL). Exp. Hematol. 20:1992;312-314.
16. Lapidot-Lifson Y., Patinkin D., Prody C.A., Ehrlich G., Seidman S., Ben-Aziz F.et al. Cloning and antisense oligodeoxynucleotide inhibition of a human homolog of cdc2 required in hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 89:1992;579-583.
17. Talpatz M., Kantarjian H., Kurzrock R., Trujillo J.M., Gutterman J.U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogeneous leukemia: Philadelphia chromosome-positive patients. Ann. Intern. Med. 114:1991;532-538.
18. Kuss B.J., Sage R.E., Shepherd K.M., Hardingham J., Nicola M. High dose hydroxyurea in collection of Philadelphia chromosome-negative stem cells in chronic myeloid leukemia. Leuk. Lymphoma. 10:1993;73-78.
19. Miyamura K., Iijima N., Itou T., Tanimoto M., Saito H. Functional expression of Fas receptor on the progenitor cells of chronic myelogeneous leukemia: induction by interferon α, γ, and bestatin. Blood. 88(Suppl. 1):1996;232a.
20. Sekine K., Fujii H., Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia. 13:1999;729-734.
21. Sekine K., Fujii H., Abe F., Nishikawa K. Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. Int. J. Cancer. 94:2001;485-491.
22. Koyama M., Hashimoto M., Asakawa N., Ishibashi M., Miyazaki H. Simultaneous determination of bestatin and p-hydoxybestatin, a major metabolite, in human serum by gas chromatography mass spectrometry. Biomed. Mass Spectrom. 7:1980;372-376.
23. Mishima Y., Matsumoto-Mishima Y., Terui Y., Katsuyama M., Yamada M., Mori M.et al. Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells. J. Natl. Cancer Inst. 94:2002;1020-1028.